This document is meant purely as documentation tool and the institutions do not assume any liability for its contents

►**B**

COMMISSION DECISION

of 14 January 2000

detailing the distribution between antigen banks of antigen reserves established within the framework of the Community action concerning reserves of foot-and-mouth disease vaccines and amending Commission Decisions 93/590/EC and 97/348/EC

(notified under document number C(2000) 1)

(Text with EEA relevance)

(2000/112/EC)

(OJ L 33, 8.2.2000, p. 21)

Amended by:

		Official Journal		
		No	page	date
►**M1**	Commission Decision 2000/707/EC of 6 November 2000	L 289	38	16.11.2000

▼B

COMMISSION DECISION

of 14 January 2000

detailing the distribution between antigen banks of antigen reserves established within the framework of the Community action concerning reserves of foot-and-mouth disease vaccines and amending Commission Decisions 93/590/EC and 97/348/EC

(notified under document number C(2000) 1)

(Text with EEA relevance)

(2000/112/EC)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Council Decision 91/666/EEC of 11 December 1991 establishing Community reserves of foot-and-mouth disease vaccines [1], as last amended by Council Decision 1999/762/EC [2], and in particular Articles 7 thereof,

Whereas:

(1) in accordance with Article 7 of Council Decision 91/666/EEC the Commission shall adopt detailed arrangements in particular with regard to the distribution of antigen reserves between antigen banks;

(2) Article 3 of Commission Decision 93/590/EC of 5 November 1993, for the purchase of foot-and-mouth disease antigens within the framework of the Community action concerning reserves of foot-and-mouth disease vaccines [3] as last amended by Decision 95/471/EC [4], makes provisions for the antigen to be stored at three specified locations;

(3) Commission Decision 97/348/EC of 23 May 1997 for the purchase by the Community of foot-and-mouth disease antigens and for the formulation, production, bottling and distribution of vaccines against foot-and-mouth disease [5], details the distribution of newly purchased antigen to designated antigen banks;

(4) by Decision 2000/111/EC [6] the Commission designated Merial SAS, Pirbright, United Kingdom as a third antigen bank and made provisions for the transfer of antigen from a bank no longer designated;

(5) as regards the quantities and types of antigen stored at designated antigen banks account must be taken of the new situation and for the sake of clarity these quantities and types of antigen should be listed for each designated antigen bank according to the new situation;

(6) the provisions of Article 3 of Decision 93/590/EC and of Article 5 of Decision 97/348/EC are no longer adapted to the new situation and should be repealed;

(7) the measures provided for in this Decision are in accordance with the opinion of the Standing Veterinry Committee,

HAS ADOPTED THIS DECISION:

Article 1

The quantities and types of antigen stored within the framework of Community reserves of foot-and-mouth disease antigen shall be distributed between designated antigen banks in accordance with the provisions in the Annex.

[1] OJ L 368, 31.12.1991, p. 21.
[2] OJ L 301, 24.11.1999, p. 6.
[3] OJ L 280, 13.11.1993, p. 33.
[4] OJ L 269, 11.11.1995, p. 29.
[5] OJ L 148, 6.6.1997, p. 27.
[6] See page 19 of this Official Journal.

▼B

Article 2

1. Article 3 of Decision 93/590/EC is repealed.

2. Article 5 of Decision 97/348/EC is repealed.

Article 3

This Decision shall apply from ►M1 1 July 2000 ◄ .

Article 4

This Decision is addressed to the Member States.

▼B

ANNEX

EUROPEAN ANTIGEN BANK	Designated antigen banks			EUROPEAN ANTIGEN BANK
	IZP Brescia	LNPB Lyon	Merial S.A.S. Pirbright	
Antigen type/subtype	Quantity (1) (× 1 000 000)	Quantity (1) (× 1 000 000)	Quantity (1) (× 1 000 000)	Quantity (1) (× 1 000 000) total per antigen
O1 — Manissa	2,5	2,5	—	5,0
O1 — BFS	—	2,5	2,5	5,0
A24 — Cruzeiro	—	2,5	2,5	5,0
A22 — Iraq	2,5	3,9	—	6,4
C1 — Noville	2,5	—	2,5	5,0
ASIA1 — Shamir	2,5	—	2,5	5,0
Quantity (1) (× 1 000 000) total per site	10,0	11,4	10,0	31,4

(1) Quantity in vaccine equivalent antigen doses.